Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.

Slides:

Advertisements

Similar presentations

IAVIs Brooklyn Design Laboratory/Historic Tax Credit Transaction By Mike Goldrich Executive Vice President & COO June 24, 2009.

Advertisements

Scaling-up the UNDP-UNEP Poverty and Environment Initiative January 2007 environment for the MDGs.

Diseases without borders What must the Global Development Community Do? World Bank Seminar Series Tawhid Nawaz, Operations Advisor Human Development Network.

Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.

Opening Doors: Federal Strategic Plan to Prevent and End Homelessness

The Effectiveness of Global Health Partnerships Findings and Lessons from a World Bank Evaluation of Global Health Programs Uma Lele April 14, 2005.

RESPONSE TO THE THEMATIC EVALUATION: INCREASING WOMEN’S LEADERSHIP AND PARTICIPATION IN PEACE AND SECURITY AND IN HUMANITARIAN RESPONSE Saraswathi Menon,

World Bank Financial Management Sector September 2010.

PEPFAR’s Approach to Maximize Efficiency, Effectiveness and Impact

Overview of the Global Fund: Guiding Principles Grant Cycle / Processes & Role of Public Private Partnerships Johannesburg, South Africa Tatjana Peterson,

Steven D. Vaughn, DVM Director Office of New Animal Drug Evaluation Center for Veterinary Medicine U. S. Food and Drug Administration June 6, 2012 Embracing.

1. 2 UN-HABITAT Current Status & Strategy for the Future.

EC Reference Document: Social Transfers in the Fight Against Hunger Nicholas Freeland Cécile Cherrier.

Global Health Program Guiding Principles April 2002.

United Nations Development Programme Oslo Governance Centre Governance & Poverty Reduction: Addressing the Social Cost of Globalization Social Forum 2008.

HIV Vaccine Clinical Trials: In Theory and on the Ground Prof. Omu Anzala Program Director Kenya AIDS Vaccine Initiative (KAVI) Department of Medical Microbiology.

11 Bill & Melinda Gates Foundation Global Libraries Initiative April 2007.

WLE and the INTEGRATING ECOSYSTEM SOLUTIONS INTO POLICY and INVESTMENTS (IES) FLAGSHIP Nathanial Matthews Global Research Coordinator IES Flagship Leader.

Implementing UNFPA’s Strategic Plan Scaling up humanitarian action Draft 6 th February 2014.

Sources of Support and What They Mean to the Field Dr. Duff Gillespie June 15 th, 2002 Africa SOTA, Nairobi.

CPTR Key Accomplishments: Research Resources Group October 3, 2012.

National Malaria Program Scale-up for Advocacy Based on Impact 23 January 2006.

The Global Fund- structure, function and evolution February 18, 2008.

IAS Members Working Together for a Stronger Health Workforce IAS General Members and Policy Meeting Sydney, 24 th July 2007.

Business and Investment Climate Reforms in Ghana – Progress, Challenges and Issues Presentation to GTZ Seminar Mount Grace Country House Hotel May 22,

WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.

Bridging Gap in Global Innovation – From need to Access, Said Business School, University of Oxford 9-13 September 2007 Strategies for Managing Innovation.

The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.

Ibero-American Road Safety Conference Madrid, February 23-24, World Bank Global Road Safety Facility.

The International Health Partnership (IHP) Anna Marriott Health Policy Officer Oxfam GB.

International Partnership for Microbicides Tessa Mattholie, European Liaison Officer, Brussels.

The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS.

Solidarity and decentralisation forms of North-South and South-South funding Local Action Creating sustainable links between North & South finance, to.

WEBINAR 3 rd UN DCF Survey on Global Accountability Office for ECOSOC Support and Coordination, UNDESA.

Education and MDGs The MDGs provided a powerful framework However, there are weaknesses: – Equity – Interconnectivity of issues – Sustainable development.

Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.

WHO EURO In Country Coordination and Strengthening National Interagency Coordinating Committees.

Report of the 2nd ad hoc Committee on the TB epidemic Jaap F. Broekmans STOP TB Partner’s Forum NEW DELHI June 2004.

Vaccine Enterprise & Collaboration Bill Snow, Director 19 January 2013 CHVI Afri-Can Forum.

OVERVIEW OF MACROECONOMIC & HEALTH KEY POINTS FROM THE OCTOBER 2003 GLOBAL CONSULTATION Briefing for Permanent Mission Representatives.

Country Partnership Strategy FY12-16 Consultations with Civil Society The World Bank Group June 2, 2011.

ROAD MAP FOR E2S RESEARCH. MAPPING E2S RESEARCH WHAT HAS BEEN DONE GAPS WHO IS DOING WHAT.

PEPFAR The Global Fund and PEPFAR: Strategic Collaboration for Greater Impact Mark Edington, Director, Grants Management, Global Fund Julia Martin, Chief.

GPOBA and Conclusions Patricia Veevers-Carter, Program Manager Global Partnership on Output-Based Aid (GPOBA) Finance, Economics and Urban Development.

The Bank’s Regional HIV/AIDS Strategies An Overview.

GLOBAL CCS INSTITUTE The Global Status of CCS: 2010 Alice Gibson – Capacity Development Manager CCS: Perspectives for the Southern African Region South.

45 th Session Advisory Committee on Health Research of the Pan American Health Organization (CAIS) Hamilton, ON, Canada 17 – 19 October 2012 Partnerships.

Richard Escritt, Director – Coordination of Community Actions DG Research, European Commission “The development of the ERA: Experiences from FP6 and reflections.

Promoting innovation through research networks: IAVI and our global partners Holly Wong International AIDS Vaccine Initiative (IAVI) August 3, 2008.

"Learning and achievements of SWA Global platform and its relevance to achieving Hygiene and Sanitation Development in India" India WASH Summit 17 th February.

GFF Third Investors Group Meeting Geneva, Switzerland June 23-24, 2016 Financing for RMNCAH: complementary financing Global Fund’s engagement with the.

Outline The Global Fund Strategy emphasizes the Key Populations

Overview and breakdown of the KPI results

European External Investment Plan

RA II Regional priorities

ROLE AND MANDATE In terms of the National Development Agency (NDA) Act (Act No 108 of 1998 as amended), NDA was mandated to contribute towards the eradication.

Global Seminar Series Human Development: Education for All

The Biodiversity and Protected Areas Management (BIOPAMA) Programme

UN Support to SDG implementation in Seychelles.

SPC - FAO Discussion on developing a Concept Note

Accessing Medicines in Africa Prospects and challenges

The Role of Bilateral Donors in supporting capacity-building in the area of ICT Open Consultations on Financing Mechanisms for Meeting the Challenges.

Reform of State Government Grants to Local Government

SPC - FAO Discussion on developing a Concept Note

Advancing Partnerships for Universal Health Coverage

Template and Process for Expression of Interest by Countries

Expected Impact and Results

The STOP TB Strategy – 2009 VISION: A TB-free world

A pathway to policy commitment for sustainability of a key population-led health services model in Thailand Dr. Preecha Prempree Deputy Director-General,

SDGs Learning and Information Platforms:

Presentation transcript:

Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb M. Abboud General Counsel September 11, 2007

International AIDS Vaccine Initiative Mission To ensure the development of a safe, effective, accessible, preventive HIV vaccine for use throughout the world 11 years old 180 staff, 5 offices (Amsterdam, Delhi, Johannesburg, Nairobi, NY), active in 23 countries $85 million annual budget Integrated R&D Program Emphasis on applied research and product development – targeting gaps and promoting rational vaccine design Industrial project management 40+ R&D partnerships 6 vaccine candidates into clinical trials Trials in 12 countries Policy & Advocacy Country and Regional Programs Sustained commitment to the developing countries Political will & finance Research & Development Clinical trials ProductionHealth & delivery systems Access & uptake

An integrated approach to speed an AIDS vaccine Mechanisms of Innovation: Implement expanded R&D program Improve the product development pipeline Address major scientific obstacles Strengthen LDC clinical testing infrastructure Secure and sustain global commitment Enhance global political and financial support Promote public policy for R&D and access Change policy environment Increase private sector engagement Enhance delivery systems Engage LDC partners Build support for trials and future demand Increase LDC science capacity Foster research consortia Refine the model Ensure efficient R&D, internal and partnership processes Innovative IP arrangements

Future Directions to Advance the Vaccine Field Screening Test of Concept Trials (STOC) Early look at efficacy through small scale trials in high-risk volunteers Prioritizing resources by allowing early failures Accelerating clinical timelines (3 to 5 years) Replicating Viral Vectors Science now indicates that replicating vectors may be necessary for an effective AIDS vaccine IAVI initiating innovative vectors program to prioritize replicating vectors Currently liaising with regulatory agencies to ensure risk analysis is commensurate with the impact of HIV Innovation Fund Funding highly novel ideas to overcome critical scientific challenges Small grants to assess proof-of-concept If successful can roll into IAVI’s product development portfolio

IAVI gratefully acknowledges the support of our donors